These cancers have been selected because their incidence in New Zealand is amongst the highest in the world.
The markers will reduce reliance on highly specialised imaging techniques only available at tertiary level hospitals. This increases health equity by removing barriers to rural communities (including marae-based care).
Importantly, development of markers for these cancers will include ways to best integrate their use into the existing and emerging cancer screening programmes.
CtDNA for better cancer management: the application of precision oncology to the New Zealand healthcare system
Science leader and principal investigator:
- Dr Rob Day, University of Otago
- Dr Rosalie Fisher, University of Auckland
- Dr Jon Mathy, Counties Manukau Health (DHB)
- Dr Dianne Sika-Paotonu, Victoria University